School of Health and Biomedical Sciences, RMIT University, 3083, Bundoora, VIC, Australia.
BMC Genomics. 2022 Mar 26;23(1):237. doi: 10.1186/s12864-022-08457-0.
Novel antimalarials should be effective across all species of malaria parasites that infect humans, especially the two species that bear the most impact, Plasmodium falciparum and Plasmodium vivax. Protein kinases encoded by pathogens, as well as host kinases required for survival of intracellular pathogens, carry considerable potential as targets for antimalarial intervention (Adderley et al. Trends Parasitol 37:508-524, 2021; Wei et al. Cell Rep Med 2:100423, 2021). To date, no comprehensive P. vivax kinome assembly has been conducted; and the P. falciparum kinome, first assembled in 2004, requires an update. The present study, aimed to fill these gaps, utilises a recently published structurally-validated multiple sequence alignment (MSA) of the human kinome (Modi et al. Sci Rep 9:19790, 2019). This MSA is used as a scaffold to assist the alignment of all protein kinase sequences from P. falciparum and P. vivax, and (where possible) their assignment to specific kinase groups/families.
We were able to assign six P. falciparum previously classified as OPK or 'orphans' (i.e. with no clear phylogenetic relation to any of the established ePK groups) to one of the aforementioned ePK groups. Direct phylogenetic comparison established that despite an overall high level of similarity between the P. falciparum and P. vivax kinomes, which will help in selecting targets for intervention, there are differences that may underlie the biological specificities of these species. Furthermore, we highlight a number of Plasmodium kinases that have a surprisingly high level of similarity with their human counterparts and therefore not well suited as targets for drug discovery.
Direct comparison of the kinomes of Homo sapiens, P. falciparum and P. vivax sheds additional light on the previously documented divergence of many P. falciparum and P. vivax kinases from those of their human host. We provide the first direct kinome comparison between the phylogenetically distinct species of P. falciparum and P. vivax, illustrating the key similarities and differences which must be considered in the context of kinase-directed antimalarial drug discovery, and discuss the divergences and similarities between the human and Plasmodium kinomes to inform future searches for selective antimalarial intervention.
新型抗疟药物应该对感染人类的所有疟原虫物种都有效,尤其是对两种对人类影响最大的疟原虫,恶性疟原虫和间日疟原虫。病原体编码的蛋白激酶以及宿主细胞内生存所需的激酶,具有作为抗疟干预靶点的巨大潜力(Adderley 等人, Trends Parasitol 37:508-524, 2021;Wei 等人,Cell Rep Med 2:100423, 2021)。迄今为止,还没有进行全面的间日疟原虫激酶组组装;而 2004 年首次组装的恶性疟原虫激酶组需要更新。本研究旨在填补这些空白,利用最近发表的人类激酶组结构验证的多重序列比对(MSA)(Modi 等人,Sci Rep 9:19790, 2019)。该 MSA 被用作支架,以协助对恶性疟原虫和间日疟原虫的所有蛋白激酶序列进行比对,并(在可能的情况下)将其分配到特定的激酶组/家族。
我们能够将之前分类为 OPK 或“孤儿”的六种恶性疟原虫(即与任何已建立的 ePK 组都没有明显的进化关系)分配到上述 ePK 组之一。直接的系统发育比较表明,尽管恶性疟原虫和间日疟原虫的激酶组之间具有高度相似性,这将有助于选择干预靶点,但存在的差异可能是这些物种的生物学特异性的基础。此外,我们还强调了一些疟原虫激酶,它们与人的对应物具有惊人的相似性,因此不太适合作为药物发现的靶点。
人类、恶性疟原虫和间日疟原虫的激酶组的直接比较进一步阐明了许多恶性疟原虫和间日疟原虫激酶与人类宿主的激酶相比已经发生了分化。我们提供了在系统发育上不同的恶性疟原虫和间日疟原虫之间的首次直接激酶组比较,说明了在激酶指导的抗疟药物发现中必须考虑的关键相似性和差异性,并讨论了人类和疟原虫激酶组之间的差异性和相似性,以指导未来有选择性的抗疟干预的搜索。